Bisphosphonate-related osteonecrosis of the jaw: background and guidelines for diagnosis, staging and management. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2006; 102: 433–441.

Bisphosphonate-mediated inhibition of osteoclast function seems to decrease bone resorption and inhibit normal bone turnover remodelling. Bone resorption and remodelling play an essential role in ...

Each bisphosphonate registration trial enrolled 3000 to 7500 patients and was powered for the demonstration of fracture efficacy, whereas the long-term extension studies, with enrollments ranging ...

On the basis of our studies, we estimated that bisphosphonate treatment would result in an annual rate of 2.3 subtrochanteric or diaphyseal fractures per 10,000 patient-years in untreated women ...

January 8, 2008 — Temporary or permanent discontinuation of bisphosphonate therapy should be considered in patients who present with severe musculoskeletal pain, the US Food and Drug ...

September 21, 2011 (San Diego, California) — Bisphosphonate therapy for osteoporosis is much more likely to be effective among patients whose blood serum levels of vitamin D are elevated ...

FDA rules out bisphosphonate, thigh fracture link By Reuters March 11, 20108:47 AM PSTUpdated March 10, 2010 ...

Treatment with the bisphosphonate zoledronate did not improve outcomes for women with chemoresistant breast cancer, according to initial results of a phase III clinical trial presented at the 2013 ...

The reduced risks for osteoporotic and hip fractures with bisphosphonate therapy outweigh increased risk for atypical femur fractures for older women, according to study finding published in Bone ...

In 2010, the FDA required makers of bisphosphonate drugs to add a warning to their labels about a small increased risk of atypical femur fractures after an American Society for Bone and Mineral ...

(HealthDay)—The risk of osteonecrosis of the jaw (ONJ) is highest in association with intravenous bisphosphonate use, according to a study published online Aug. 19 in the Journal of Bone and ...

Intravenous (IV) bisphosphonates reduce the risk of skeletal-related events in patients with multiple myeloma (MM). However, data describing racial differences in IV bisphosphonate utilization outside ...